MTOR and familial pancreatic carcinoma: Another study revealed that MAPK (87%), PI3K/AKT/mTOR (19%), DNA repair (15%), cell cycle (11%), and AKT/mTOR (19%) pathway alterations were present in pancreatic cancer patients (21).